Agenus to Host March 2026 Stakeholder Webcast: Advancing BOT+BAL Across Tumor Types and Expanding Patient Access

Agenus will host a March Stakeholder Webcast to discuss the progress of its botensilimab and balstilimab (BOT+BAL) immunotherapy program, patient access programs, and development across tumor types. The session will be moderated by Garo Armen, PhD, and will feature topics including clinical progress, durability, and consistency across tumors, and access and execution of global programs. The webcast will also include a live Q&A session.